Just one thing stands between some Type 2 diabetes patients and disease management: a dislike of needles. A new pill form of semaglutide, a medicine that aids in digestion and blood sugar regulation, could make treatment more feasible for these patients – improving lives and lowering overall health care costs.
But the Institute for Clinical and Economic Review has other ideas.
The controversial Boston-based health economics organization released a new evidence report that deems oral semaglutide not cost effective. Perhaps that’s because ICER omits or undervalues several key factors in its calculation.